{"name":"mAbxience Research S.L.","slug":"mabxience-research-s-l","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"EU-approved Avastin®","genericName":"EU-approved Avastin®","slug":"eu-approved-avastin","indication":"Metastatic colorectal cancer","status":"phase_3"},{"name":"EU-Opdivo®","genericName":"EU-Opdivo®","slug":"eu-opdivo","indication":"Metastatic non-small cell lung cancer","status":"phase_3"},{"name":"MB09 (denosumab biosimilar)","genericName":"MB09 (denosumab biosimilar)","slug":"mb09-denosumab-biosimilar","indication":"Prevention of skeletal-related events in patients with bone metastases from solid tumors","status":"phase_3"},{"name":"RTXM83","genericName":"RTXM83","slug":"rtxm83","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"US licenced Avastin®","genericName":"US licenced Avastin®","slug":"us-licenced-avastin","indication":"Other","status":"phase_1"},{"name":"US- sourced Opdivo®","genericName":"US- sourced Opdivo®","slug":"us-sourced-opdivo","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"EU-approved Avastin®","genericName":"EU-approved Avastin®","slug":"eu-approved-avastin","phase":"phase_3","mechanism":"Avastin (bevacizumab) is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF), preventing tumor blood vessel formation and starving tumors of oxygen and nutrients.","indications":["Metastatic colorectal cancer","Metastatic non-small cell lung cancer","Metastatic breast cancer","Glioblastoma","Metastatic renal cell carcinoma"],"catalyst":""},{"name":"EU-Opdivo®","genericName":"EU-Opdivo®","slug":"eu-opdivo","phase":"phase_3","mechanism":"EU-Opdivo® is a PD-1 checkpoint inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby restoring anti-tumor immune responses.","indications":["Metastatic non-small cell lung cancer","Melanoma","Renal cell carcinoma","Hodgkin lymphoma","Head and neck squamous cell carcinoma"],"catalyst":""},{"name":"MB09 (denosumab biosimilar)","genericName":"MB09 (denosumab biosimilar)","slug":"mb09-denosumab-biosimilar","phase":"phase_3","mechanism":"MB09 is a biosimilar of denosumab that inhibits RANKL (receptor activator of nuclear factor kappa-B ligand) to suppress osteoclast formation and bone resorption.","indications":["Prevention of skeletal-related events in patients with bone metastases from solid tumors","Treatment of osteoporosis in postmenopausal women and men at high risk of fracture","Giant cell tumor of bone"],"catalyst":""},{"name":"RTXM83","genericName":"RTXM83","slug":"rtxm83","phase":"phase_3","mechanism":"RTXM83 is a monoclonal antibody targeting PD-L1.","indications":["Non-small cell lung cancer, PD-L1 positive"],"catalyst":""},{"name":"US licenced Avastin®","genericName":"US licenced Avastin®","slug":"us-licenced-avastin","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"US- sourced Opdivo®","genericName":"US- sourced Opdivo®","slug":"us-sourced-opdivo","phase":"phase_3","mechanism":"Opdivo is a PD-1 inhibitor that works by blocking the PD-1 receptor on T cells, allowing them to attack cancer cells.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxOU3hfa0JPVU9zTXZWc1A0WkRUYVhLZlB3c1RPc1FxVU1mSFBlN0lQT0tOMHlvbXJwRlZMbFhxdV9zTkxfWXBkUFdGcWZaQkFRMHpNMWFvUGpTVjlHZzluYXp4QXI5TlJrT0NXR2JwMGFrd3hZeFdyUzVuR0NuZnVuSkEzdjRRUEFqWXhPUjhsRXBEeUFIZl9jLVc1VVoyaHRmWFRVTWw0S3pFOV9xMlYzU2RpR2ZEV1dieWpjRTd4eElFY2V6UkdhdWNOd0NUUXk1Um95SjhVNHRRRUxXNGtzc2d4a2NkcjN3YmlUWEZCWTlkc2U4YlNyMW50XzFzdw?oc=5","date":"2026-02-16","type":"trial","source":"Investing News Network","summary":"IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Investing News Network","headline":"IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxQQzRRaWxaX0Y4TVVjdVdRREgyYjFaVDZRMjJBak1mSGxUdC1WOWV5b0VGUW90RGcyQ05fcXh4RkNyRzdvSmJQMy1fc1M5UmNPWEFGZDlkalJXRmEyYTlvTlpuMWd6RTF0d1JPZzJHY0lZWkE5MjZ5MVpTbzRVOHJnczBR?oc=5","date":"2026-01-22","type":"regulatory","source":"JD Supra","summary":"How the U.S. Compares to Europe on Biosimilar Approvals and Products In the Pipeline - Updated January 22, 2026 - JD Supra","headline":"How the U.S. Compares to Europe on Biosimilar Approvals and Products In the Pipeline - Updated January 22, 2026","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxQWFJsRTBmdmZWR1I3TDdXMVRhdWxxLWUwQURvb0ZxRFY1RURrc1lZYWU2Zm12TUs2QXJYVkZqdm8tb3Fxdk9iZ0ZwbHNNb0Z3bGJ3Y0Y2aFRvMUtkaU1HMFdBWnJ5VmZlb3JzZGlCNHQxSnBQMXZNV0NDZWlnc1l2bmdWaVkyN0U3TmdRQnZQc1c2MEZBY3g5OGRRb0REdGpsTVJOeHhLaGl3SUQ5OXFCeXU5Yw?oc=5","date":"2025-04-25","type":"regulatory","source":"European Medicines Agency (EMA)","summary":"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 April 2025 - European Medicines Agency (EMA)","headline":"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 April 2025 - European Medicines ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTE00c3pYMXhsVmlCOVN1MmlKamM2M01PQ2dYQ3g4ZFFVR1VrajBLVkVzR3pLQzFqM0trVE9GY0ZIQlYwWFlueTZZT3d0M1dxWHN2b2dSNkJqLVlfRzN6Njltcjc5NHBTY25TRDFR?oc=5","date":"2025-04-09","type":"regulatory","source":"ec.europa.eu","summary":"EU Regulatory Oncology Newsletter - April 2025 - ec.europa.eu","headline":"EU Regulatory Oncology Newsletter - April 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxNRlA3MldGV1BTUTgzeWhyZ0owcGtYeDFRZWprSjZfLVJMZGlOTE9qMU4tNWo5N3ZEajlEVUlIT1M5TlN0b29wVjNUdTM3c2Vpem1aeTFjNS1YVUVEd0g1b0NyalltUGZnbHkxYlV4MC1OWmpFYVRjZExDT3RVOHZOTmNB?oc=5","date":"2025-01-14","type":"regulatory","source":"JD Supra","summary":"How the U.S. Compares to Europe on Biosimilar Approvals and Products In the Pipeline - Updated January 13, 2025 - JD Supra","headline":"How the U.S. Compares to Europe on Biosimilar Approvals and Products In the Pipeline - Updated January 13, 2025","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxQcVdIbE5WV1hWZjVDNVN2RTZUalUwZVFvdk15TWdpajZyRWkyNEhDeHRUVkJzTXRxVVRXdWY2dzRLZjhGMlFZQndLWlJTUjM2OGNreFlEN3F0VWhCMDdzUE84cVlhM09FT3h3QzRrZUZFeXFJWEVjZUVRN3RrVnRVUWZHd3VsUXpzNXNhdHhQWFY0OEk?oc=5","date":"2024-02-07","type":"pipeline","source":"Contract Pharma","summary":"mAbxience and Biosidus Enter CDMO Agreement - Contract Pharma","headline":"mAbxience and Biosidus Enter CDMO Agreement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxPX3g3dFE4QUREcHprUjkwdVpseWFNaGFUMkRuOElvWnQ0RFhKVEZrcmJRV0lrUnAzOVpIYTc3dmVOanFpM0huRDNXWjRmQjRwSjJBSUg0UDlWdTZyT2tobkcwRGN5U2NNSmtKWW4tNEhvT3Q2MWd4N3kyeVF5YTlTTFJIbWdZUUhwM1dKRm53ZmFwYUJ0WjE3MC1BbF94dw?oc=5","date":"2023-09-21","type":"deal","source":"Pharmaceutical Executive","summary":"Abbott, mAbxience Holdings Strike Biosimilars Commercialization Deal - Pharmaceutical Executive","headline":"Abbott, mAbxience Holdings Strike Biosimilars Commercialization Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxQUXFDZjFyNURkQjZQQzR0LWlfOHhSNTRlcUhOM3A4emhHQnU5RUs3cWdPSFFQN05IM1pzZXZrVFJLUi0xX1N5VEdGVEVzdGpTVjNORmFsbGYtR0Nsa2E5OHI0R0Y2YkpHOGVNelVOdHcwc0pTRmRFMDZ1bGsyVDRLWV8ycnpvNlNFNmlMMkNHV2hJbGZ0Q2haaUptaFFZMFplbTdCaTZzWEJfMEEtMXF2RWpGaDRXVlNKeUZILWpBUXZlaTNERXpSNUl3?oc=5","date":"2023-09-20","type":"patent","source":"PR Newswire","summary":"Abbott Broadens Access to Cutting-Edge Biosimilars in Key Emerging Markets - PR Newswire","headline":"Abbott Broadens Access to Cutting-Edge Biosimilars in Key Emerging Markets","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggFBVV95cUxPRWhnb3VHVFRXeTJUR3BqaVFtOUEyVXlDNTNVd1RTdV9DQVFWaXZlTGYtV3prblpmUnMtOVNOZjc4N05qb2RsTzVKNDBOOGxUeXVNcFlDTE1EQ0VNdTA2WkxFU0ZDbTN0T1JLdmJKc2hHdkx2a3BDRVpidHFrR1RITW9B?oc=5","date":"2022-03-16","type":"regulatory","source":"JD Supra","summary":"How the U.S. Compares to Europe on Biosimilar Approvals and Products In the Pipeline Updated March 14, 2022 - JD Supra","headline":"How the U.S. Compares to Europe on Biosimilar Approvals and Products In the Pipeline Updated March 14, 2022","sentiment":"positive"}],"patents":[],"drugCount":6,"phaseCounts":{"phase_3":5,"phase_1":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}